Eli Lilly's retatrutide posted its first full Phase 3 diabetes results on June 6, 2026 — simultaneously presented at the 86th ADA Scientific Sessions in New Orleans and published in The Lancet. The triple agonist cut HbA1c by up to 1.94 percentage points and drove 15.3% body weight loss in adults with type 2 diabetes at 40 weeks. Lead investigator Harpreet Bajaj called the weight reduction "quite staggering" for a diabetes population.
Research-context information only. Retatrutide is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
The TRANSCEND-T2D-1 Numbers
TRANSCEND-T2D-1 randomized 537 adults with recent-onset type 2 diabetes (mean duration 2.5 years) who had inadequate glycemic control on diet and exercise alone. Baseline HbA1c ranged 7.0–9.5% and BMI was 23 kg/m² or higher. Participants were randomized 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg, or placebo, dosed once weekly by subcutaneous injection with escalation from a 2 mg starting dose. This was a monotherapy trial — retatrutide alone, no background diabetes medication.
40-week efficacy (primary endpoint — HbA1c):
| Dose | A1C Reduction | Weight Loss |
|---|---|---|
| 12 mg | -1.94% | 15.3% |
| 9 mg | -1.86% | 13.9% |
| 4 mg | -1.69% | 11.5% |
| Placebo | -0.81% | 2.6% |
All three doses hit the primary endpoint with p<0.0001. The headline for clinicians is the A1C drop: a nearly 2-point reduction from a 40-week monotherapy is at the top of what any incretin therapy has shown in this population. The headline for everyone else is the weight loss — 15.3% in people with diabetes, when diabetes trials historically show smaller weight effects than obesity trials because of differing metabolism and baseline medication.
Beyond glucose and weight, retatrutide improved non-HDL cholesterol, triglycerides, and systolic blood pressure across the higher doses — the cardiometabolic cluster that drives long-term outcomes in diabetes.
How It Fits the TRIUMPH Picture
TRANSCEND-T2D-1 is the diabetes counterpart to the obesity TRIUMPH program. The two read out very differently by design:
| Trial | Population | Duration | Top-Dose Result |
|---|---|---|---|
| TRANSCEND-T2D-1 | Type 2 diabetes | 40 wk | -1.94% A1C, 15.3% weight |
| TRIUMPH-1 | Obesity, no diabetes | 80–104 wk | 28.3% weight (80 wk), 30.3% (104 wk) |
The obesity trial ran longer and enrolled people without diabetes, so its weight numbers are larger. But the diabetes result is arguably the more clinically loaded one: a near-2-point A1C reduction plus double-digit weight loss from a single weekly injection, with no add-on drugs, is the kind of data that reshapes diabetes treatment guidelines. We broke down the obesity readout in the TRIUMPH-1 30% weight-loss analysis.
Safety Profile
The adverse-event pattern matched the incretin class. Gastrointestinal events led: nausea (16.4–26.5% across doses vs 3.7% placebo), diarrhea (18.7–26.3% vs 4.5%), and vomiting (15.0–17.6% vs 2.2%). Dysesthesia — the abnormal skin sensation first flagged in TRIUMPH-4 — appeared in 2.3–4.5% of the retatrutide arms, described as mild and generally resolving. Discontinuation rates due to adverse events stayed low at 2.2–5.1%.
The dysesthesia signal is worth tracking because it is unique among the GLP-1-class compounds and tied to retatrutide's glucagon-receptor agonism. We covered the mechanism and the community's management approaches in the retatrutide dysesthesia breakdown.
